ArticleTargeted oncology2020

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.

Haiyan Xu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.